Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin vs UFH in ACS
NCT00077818Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2002
- Primary completion
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in acute coronary syndrome (ACS) (2 arms), sponsored by Sanofi. Primary endpoint: Composite of all-cause mortality, non-fatal MI, or recurrent angina requiring revascularization at 30 days. Started Jun 2002; status: completed.
02
Drugs
enoxaparin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00077818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077818.